2023
Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
Mashayekhi M, Nian H, Mayfield D, Devin J, Gamboa J, Yu C, Silver H, Niswender K, Luther J, Brown N. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes. Diabetes 2023, 73: 38-50. PMID: 37874653, PMCID: PMC10784656, DOI: 10.2337/db23-0356.Peer-Reviewed Original ResearchConceptsEndogenous GLP-1Glucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsImproved insulin sensitivityInsulin sensitivityGLP-1GLP-1RGlucagon levelsGlucose levelsMatsuda indexWeight lossHypocaloric dietPostprandial glucoseInhibitor sitagliptinReceptor agonistMetabolic effectsDiet-induced weight lossDipeptidyl peptidase-4 inhibitor sitagliptinGLP-1R agonist liraglutideWeight loss-independent effectsDPP-4 inhibitor sitagliptinDipeptidyl peptidase-4 inhibitionPeptidase-4 inhibitionMixed meal testGLP-1R antagonistEffect of the glucagon‐like peptide‐1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes
Silver H, Olson D, Mayfield D, Wright P, Nian H, Mashayekhi M, Koethe J, Niswender K, Luther J, Brown N. Effect of the glucagon‐like peptide‐1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes. Diabetes Obesity And Metabolism 2023, 25: 2340-2350. PMID: 37188932, PMCID: PMC10544709, DOI: 10.1111/dom.15113.Peer-Reviewed Original ResearchMeSH KeywordsAdultAppetiteBody Fat DistributionBody WeightCaloric RestrictionCardiovascular DiseasesDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDipeptidyl-Peptidases and Tripeptidyl-PeptidasesEatingGlucagon-Like Peptide-1 ReceptorHumansHypoglycemic AgentsLiraglutideObesityPrediabetic StateSitagliptin PhosphateWeight LossConceptsGlucagon-like peptide-1 receptor agonist liraglutidePeptide-1 receptor agonist liraglutideLiraglutide groupSitagliptin groupCR groupCaloric restrictionChi-squared testDietary intakeWeight lossBody weightBody compositionDipeptidyl peptidase-4 inhibitor sitagliptinDipeptidyl peptidase-4 inhibitorsDual-energy X-ray absorptiometryEnergy X-ray absorptiometryInsulin resistance scoreBaseline body weightHomeostatic model assessmentPeptidase-4 inhibitorsCardiometabolic risk reductionBody fat distributionVisual analog scaleWeeks of interventionPersonal risk factorsX-ray absorptiometry
2022
Comparative effects of weight loss and incretin‐based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial
Mashayekhi M, Beckman JA, Nian H, Garner EM, Mayfield D, Devin JK, Koethe JR, Brown JD, Cahill KN, Yu C, Silver H, Niswender K, Luther JM, Brown NJ. Comparative effects of weight loss and incretin‐based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial. Diabetes Obesity And Metabolism 2022, 25: 570-580. PMID: 36306151, PMCID: PMC10306232, DOI: 10.1111/dom.14903.Peer-Reviewed Original ResearchConceptsFlow-mediated vasodilationPlasminogen activator inhibitor-1Vascular endothelial functionEndothelial functionInsulin resistanceWeight lossGlucagon-like peptide-1 receptor agonistsBaseline flow-mediated vasodilationDipeptidyl peptidase-4 inhibitor sitagliptinGLP-1R agonist liraglutideWeight loss-independent mechanismsPeptide-1 receptor agonistsBeneficial effectsEndothelial vasodilator functionGreater endothelial dysfunctionIncretin-based therapiesNormal endothelial functionChemoattractant protein-1Chemokine MCP-1Significant weight lossActivator inhibitor-1Effect of treatmentVasodilator functionUrine albuminEndothelial dysfunction
2018
The Vasculature in Prediabetes
Wasserman DH, Wang TJ, Brown NJ. The Vasculature in Prediabetes. Circulation Research 2018, 122: 1135-1150. PMID: 29650631, PMCID: PMC5901903, DOI: 10.1161/circresaha.118.311912.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin-Converting Enzyme InhibitorsAnimalsBlood VesselsCardiovascular DiseasesCombined Modality TherapyDiabetes Mellitus, Type 2Diet, ReducingDisease ProgressionEndothelium, VascularExtracellular MatrixFatty Acids, NonesterifiedFibrinolysisGlucoseHumansHyperglycemiaHypoglycemic AgentsInflammationInsulin ResistanceLife StyleMetabolic SyndromeMiceMicrocirculationMicroRNAsMuscle, SkeletalObesityPrediabetic StateRiskWeight LossConceptsFrequency of prediabetesMainstay of treatmentPrevalence of obesityConcomitant obesityEndothelial dysfunctionExtracellular matrix remodelingDiabetes mellitusEndothelial functionRenal diseaseMetabolic derangementsFibrinolytic dysfunctionEndothelial vasodilatorsInsulin resistanceInsulin sensitivityCardiovascular diseaseDelivery of insulinSlow progressionPrediabetesWeight lossSkeletal muscleMatrix remodelingMellitusObesityDysfunctionDisease